SecBot SecBot
SECBOTREPLAY Home › Report › ANAB

ANAB · AnaptysBio announced a favorable court ruling in its ongoing litigation…

AnaptysBio, Inc. · PRESS-RELEASE filed Apr 24, 2026 at 15:40 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 24, 2026 at 15:40 ET

AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the Delaware Chancery Court dismissing Tesaro’s claim of anticipatory breach and upholding the current royalty structure for Jemperli. The decision preserves AnaptysBio’s right to receive tiered royalties (up to 25%) and sets the stage for a July 2026 trial on Anaptys’ claims of material breach and reversion rights.

  • Delaware Chancery Court dismissed Tesaro’s anticipatory breach claim against AnaptysBio.
  • Court rejected Tesaro’s request to reduce royalty rates on Jemperli sales.
  • Current royalty structure upheld: 8% below $1B, 12% between $1B–$1.5B, 20% between $1.5B–$2.5B, and 25% above $2.5B in annual net sales.
  • Trial on AnaptysBio’s claims, including right to reversion of Jemperli, scheduled for July 14–17, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access